- ASCO® 2024
- Yale Cancer Answers
- ASH CME Series
- Smilow Shares with Primary Care
- Grand Rounds
- Head and Neck
- Gynecologic
- Benign Hematology
- Breast
- GI
- Lung
- GU
- Hematologic Oncology
- Brain
- Cancer Screening
- DEI (Diversity, Equity and Inclusion)
- 2021 ASH Highlights
- General Events
- Events
Playback speed
10 seconds
Safety, Efficacy, and Biomarker Analysis of a Phase 1 Study of PLK1 Onvansertib + Low-Dose Cytarabine or Decitabine in Relapsed/Refractory AML
By
Yale Cancer Center
FEATURING
Amer Zeidan
By
Yale Cancer Center
FEATURING
Amer Zeidan
99 views
January 24, 2020
Comments 0
Login to view comments.
Click here to Login
Hematologic Oncology